Bala Attili1, Sofie Celen1, Muneer Ahamed1, Michel Koole2, Chris Van Den Haute3,4, Wim Vanduffel5, Guy Bormans1. 1. Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. 2. Department of Nuclear Medicine and Molecular Imaging, UZ Gasthuisberg, Leuven, Belgium. 3. Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Leuven, Belgium. 4. Leuven Viral Vector Core, Molecular Medicine, KU Leuven, Leuven, Belgium. 5. Laboratory for Neuro- and Psychophysiology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Abstract
BACKGROUND AND PURPOSE: Non-invasive in vivo imaging of cannabinoid CB2 receptors using PET is pursued to study neuroinflammation. The purpose of this study is to evaluate the in vivo binding specificity of [18 F]MA3, a CB2 receptor agonist, in a rat model with local overexpression of human (h) CB2 receptors. METHODS: [18 F]MA3 was produced with good radiochemical yield and radiochemical purity. The radiotracer was evaluated in rats with local overexpression of hCB2 receptors and in a healthy non-human primate using PET. KEY RESULTS: Ex vivo autoradiography demonstrated CB2 -specific binding of [18 F]MA3 in rat hCB2 receptor vector injected striatum. In a PET study, increased tracer binding in the hCB2 receptor vector-injected striatum compared to the contralateral control vector-injected striatum was observed. Binding in hCB2 receptor vector-injected striatum was blocked with a structurally non-related CB2 receptor inverse agonist, and a displacement study confirmed the reversibility of tracer binding. This study identified the utility of mutated inactive vector model for evaluation of CB2 receptor agonist PET tracers. [18 F]MA3 PET scans in the non-human primate showed good uptake and fast washout from brain, but no CB2 receptor-specific binding was observed. CONCLUSION AND IMPLICATIONS: Evaluation of [18 F]MA3 in a rat model with local overexpression of hCB2 receptors showed CB2 receptor-specific and reversible tracer binding. [18 F]MA3 showed good brain uptake and subsequent washout in a healthy non-human primate, but no specific binding was observed. Further clinical evaluation of [18 F]MA3 in patients with neuroinflammation is warranted. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
BACKGROUND AND PURPOSE: Non-invasive in vivo imaging of cannabinoid CB2 receptors using PET is pursued to study neuroinflammation. The purpose of this study is to evaluate the in vivo binding specificity of [18 F]MA3, a CB2 receptor agonist, in a rat model with local overexpression of human (h) CB2 receptors. METHODS: [18 F]MA3 was produced with good radiochemical yield and radiochemical purity. The radiotracer was evaluated in rats with local overexpression of hCB2 receptors and in a healthy non-human primate using PET. KEY RESULTS: Ex vivo autoradiography demonstrated CB2 -specific binding of [18 F]MA3 in rat hCB2 receptor vector injected striatum. In a PET study, increased tracer binding in the hCB2 receptor vector-injected striatum compared to the contralateral control vector-injected striatum was observed. Binding in hCB2 receptor vector-injected striatum was blocked with a structurally non-related CB2 receptor inverse agonist, and a displacement study confirmed the reversibility of tracer binding. This study identified the utility of mutated inactive vector model for evaluation of CB2 receptor agonist PET tracers. [18 F]MA3 PET scans in the non-human primate showed good uptake and fast washout from brain, but no CB2 receptor-specific binding was observed. CONCLUSION AND IMPLICATIONS: Evaluation of [18 F]MA3 in a rat model with local overexpression of hCB2 receptors showed CB2 receptor-specific and reversible tracer binding. [18 F]MA3 showed good brain uptake and subsequent washout in a healthy non-human primate, but no specific binding was observed. Further clinical evaluation of [18 F]MA3 in patients with neuroinflammation is warranted. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
Authors: Brady K Atwood; James Wager-Miller; Christopher Haskins; Alex Straiker; Ken Mackie Journal: Mol Pharmacol Date: 2011-11-07 Impact factor: 4.436
Authors: Stephen Ph Alexander; Arthur Christopoulos; Anthony P Davenport; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Romana Meletta; Roger Slavik; Linjing Mu; Zoran Rancic; Nicole Borel; Roger Schibli; Simon M Ametamey; Stefanie D Krämer; Adrienne Müller Herde Journal: Nucl Med Biol Date: 2017-01-08 Impact factor: 2.408
Authors: Sofie Celen; Michel Koole; Meri De Angelis; Ivan Sannen; Satish K Chitneni; Jesus Alcazar; Stefanie Dedeurwaerdere; Dieder Moechars; Mark Schmidt; Alfons Verbruggen; Xavier Langlois; Koen Van Laere; José Ignacio Andrés; Guy Bormans Journal: J Nucl Med Date: 2010-09-16 Impact factor: 10.057
Authors: Andrew G Horti; Yongjun Gao; Hayden T Ravert; Paige Finley; Heather Valentine; Dean F Wong; Christopher J Endres; Alena V Savonenko; Robert F Dannals Journal: Bioorg Med Chem Date: 2010-05-25 Impact factor: 3.641
Authors: Nele Evens; Barbara Bosier; Brian J Lavey; Joseph A Kozlowski; Peter Vermaelen; Luc Baudemprez; Roger Busson; Didier M Lambert; Koen Van Laere; Alfons M Verbruggen; Guy M Bormans Journal: Nucl Med Biol Date: 2008-10 Impact factor: 2.408
Authors: Ruiqing Ni; Adrienne Müller Herde; Ahmed Haider; Claudia Keller; Georgios Louloudis; Markus Vaas; Roger Schibli; Simon M Ametamey; Jan Klohs; Linjing Mu Journal: Mol Imaging Biol Date: 2021-10-12 Impact factor: 3.484
Authors: Lu Hou; Jian Rong; Ahmed Haider; Daisuke Ogasawara; Cassis Varlow; Michael A Schafroth; Linjing Mu; Jiefeng Gan; Hao Xu; Christopher J Fowler; Ming-Rong Zhang; Neil Vasdev; Simon Ametamey; Benjamin F Cravatt; Lu Wang; Steven H Liang Journal: J Med Chem Date: 2020-12-30 Impact factor: 7.446
Authors: Vasil Kecheliev; Francesco Spinelli; Adrienne Herde; Ahmed Haider; Linjing Mu; Jan Klohs; Simon M Ametamey; Ruiqing Ni Journal: Front Aging Neurosci Date: 2022-09-30 Impact factor: 5.702
Authors: Erik Nutma; Kelly Ceyzériat; Sandra Amor; Stergios Tsartsalis; Philippe Millet; David R Owen; Vassilios Papadopoulos; Benjamin B Tournier Journal: Eur J Nucl Med Mol Imaging Date: 2021-01-12 Impact factor: 9.236